STEM CELL SCIENCES OPENS OFFER FOR A CAPITAL RAISING OF UP TO $12 MILLION AND DUAL LISTING ON THE AUSTRALIAN STOCK EXCHANGE

20 March 2007. Stem Cell Sciences plc ("SCS") is pleased to announce that it has formally opened it's offer to raise up to A$12 million via a prospectus issue through the issue of up to 11.2 million new securities at an issue price of A$1.07 per new security.

SCS has a primary listing on the London Stock Exchange's Alternative Investment Market (AIM) and following the closure of this capital raising will have a dual listing on the Australian Stock Exchange.

The raising of funds under the offer is consistent with the Company's plans as of the July 2005 AIM flotation and will be used to fund product development, business expansion and initial support of collaborative programs for pre-clinical evaluation of SCS cells in animal models of human neurological disease.

SCS funding and development will be targeted particularly at revenue creation opportunities and adding value to the company through early stage validation of its therapeutic pipeline.

The key dates are as follows:

Prospectus lodged with ASIC	9 March 2007
Opening Date	20 March 2007
Broker firm applications due	3 April 2007
Closing date	5 April 2007
Expected date for dispatch of transaction confirmation statements	6 April 2007
Expected date for the quotation of securities on ASX	12 April 2007

The Board has the discretion to close this offer early.

BioTech Capital is the third largest shareholder of SCS and has Board representation.

Full press release from Stem Cell Sciences attached.

About BioTech Capital Ltd

BioTech Capital Ltd ("BTC") is one of Australia's largest life-science focused private equity funds. With approximately $12 million in investment funds still available, the company is well placed to continue to develop a diversified portfolio of high quality Australian life-science investments.

BTC currently has investments in a diverse group of Australian life-science companies including Alchemia, Biocomm, Continence Control Systems, Pacific Knowledge Systems, Phylogica, Prima Biomed, Starpharma, Stem Cell Sciences and XRT. As a registered Pooled Development Fund (PDF), investors are generally exempt from tax on capital gains and income.

BTC is listed on the Australian Stock Exchange (Code: BTC) and is managed externally by Titan BioVentures Management (www.titanbioventures.com).

Additional information can be found at www.biotechcapital.com.au

www.biotechcapital.com.au

Press Release

Stem Cell Sciences Opens Dual Listing Share Offer on ASX

("Stem Cell Sciences", "SCS" or "the Company")

20 March, 2007

Melbourne, Australia: Stem Cell Sciences plc (AIM:STEM), the global biotechnology company focused on the commercialisation of stem cells and stem cell technologies in research and cell-based therapies, is pleased to announce the opening of its share offer to raise a minimum of $10 million with oversubscriptions up to $12 million through the issue of 9.3 to 11.2 million shares in the form of CHESS Depositary Interests (CDIs)* at $1.07 per share. SCS' shares will continue to be traded on the Alternative Investment Market of the London Stock Exchange and the Company will dual list on the Australian Stock Exchange (ASX).

SCS specialises in both adult and embryonic stem cells and has an established record of securing research and licensing agreements with international biotechnology and pharmaceutical companies. The key challenges for the successful application of stem cells are their safe, robust and reproducible growth and differentiation. SCS has developed the products and technologies needed to address these challenges.

The Company is engaged in all aspects of the stem cell value chain from academic research reagents through supply of cells for drug discovery and future stem cell-based therapies. The Company has four business units. Three of these business units support research use of stem cells through the development of stem cell culture media and research reagents, the licensing of enabling stem cell technologies, and cell production and genetic engineering services for use in drug discovery. The research focused business units are already generating revenues and improving SCS cell production capability needed to minimise the costs associated with the development of cell-based therapies.

SCS has licensed technology to major pharmaceutical and biotechnology companies including Merck & Co., Pfizer, Sanofi Aventis, GlaxoSmithKline, Deltagen Inc, Lexicon Genetics Inc. and others. The first commercially available product, a novel, serum free, mouse stem cell growth medium, was launched in February 2006. This was followed by "HEScGRO™", the first animal-component free cell culture medium to enable improved growth of human embryonic stem cells, in January 2007. These products are manufactured and distributed by Chemicon International, now part of Millipore Corporation.

"We are very pleased to be expanding our Australian shareholder base in parallel with our growing international business opportunities. SCS will continue to build on its global footprint and is well positioned to take advantage of the expanding markets in the stem cell field," said Dr. Peter Mountford, Chief Executive Officer of Stem Cell Sciences.

www.biotechcapital.com.au

"The biggest challenge for the stem cell field is stable, reproducible production of stem cells and their differentiation products. This is our core competency and our technologies and products continue to be specifically developed to address these key challenges." he added.

The funds raised will be used to advance the Company's revenue generating business units and support SCS' expansion into the USA. Funds will also be used for research and development of the Company's pre-clinical pipeline of therapeutic candidates for neurological disease.

SCS commenced operations in Melbourne, Australia in 1994 and relocated its headquarters to Edinburgh, UK in 2003. The Company maintains operations in Melbourne (Australia), Edinburgh and Cambridge (UK), San Francisco (USA), and via its affiliated company, SCS KK, in Kobe, Japan. Stem Cell Sciences is expected to list on the Australian Stock Exchange in April 2007.

* CHESS Depositary Interests – The main difference between holding CDIs and Shares is that the holder of CDIs has beneficial ownership of the underlying Shares instead of legal title. CHESS Depositary Nominees Pty Ltd, a wholly owned subsidiary of ASX, holds the legal title to the underlying Shares. Holders of CDIs will have the same economic benefits of holding the underlying Shares. In particular, holders of CDIs will be able to transfer and settle transactions electronically on the ASX.

The offer of shares in Stem Cell Sciences will be made in, or accompanied by, a copy of the prospectus. Anyone wishing to acquire shares in Stem Cell Sciences will need to complete an application form that will be in, or will accompany, the prospectus. The prospectus and offer are only available to residents of Australia.

The prospectus is downloadable at www.bellpotter.com.au

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing reporting.

- Ends -

For further information, please contact:

Stem Cell Sciences
David Campbell
Group Business Development Manager +61 3 9905 0600 or
david.campbell@stemcellsciences.com (0)408 106 949

Talk Biotech
Fay Weston +61 (0)422 206036
fayweston@talkbiotech.com.au

Notes to Editors

Stem Cell Sciences plc (SCS, AIM: STEM) is a global biotechnology company, established in Melbourne, Australia in 1994, providing products in the burgeoning stem cell research and drug discovery markets, in addition to the targeted development of cell-based therapies for neurodegenerative disease and injury.

The Company has established a leading intellectual property (IP) and technology portfolio that enables the commercial application of stem cells in drug discovery, providing the Company with early-stage revenue streams and technology development for at scale cell production of SCS cell-based therapeutics. SCS principal focus is in neurological disease. Revenues in the neurotech market, including pharmaceuticals, devices and diagnostics, grew 10% in 2005 to US$110 billion [*Neurotech Insights, Volume 2/3 April 30 2006*].

SCS operates as a group of independent operations with offices and laboratories in Edinburgh and Cambridge, UK, Kobe, Japan, Melbourne, Australia and San Francisco, USA (office only). Each SCS facility is affiliated with an academic centre of excellence. These include the Institute of Stem Cell Research (ISCR), Edinburgh, UK, RIKEN Centre for Development Biology, Kobe, Japan and the Australian Stem Cell Centre, Melbourne, Australia.

SCS has four business units, each dedicated to different aspects of the stem cell business opportunity.

SC Proven® provides cell culture media (liquid formulations) and reagents that enable the growth and differentiation of stem cells. The first SC Proven® product, "ESGRO Complete™", a cell culture medium capable of consistent growth of mouse embryonic stem cells without serum or feeder cell support was launched in February 2006. This was followed by "HEScGRO™", the first animal-component free cell culture medium to enable improved growth of human embryonic stem cells, in January 2007. These products are manufactured and distributed by Chemicon International, now part of Millipore Corporation.

SC Licensing licenses SCS proprietary technologies, such as Internal Ribosome Entry Site (IRES), Stem Cell Selection, hMADS (human adipose derived stem cells) and Neural Stem Cell Technology for application in laboratory-based research and discovery. SCS has licensed technology to major pharmaceutical and biotechnology companies including Merck & Co, Pfizer, Sanofi Aventis, GSK, Deltagen Inc and Lexicon Genetics Inc and others.

SC Services provides specialised stem cell production for basic research and drug discovery, including high-throughput applications through an automated cell production facility in Cambridge UK. The services offered include the creation of specific cell lines for a customer, the modification of existing cell lines so that they can be grown in serum free SC Proven® media, and the supply of cells for drug screening in multi-well plate format.

SC Therapies' goal is to develop safe and effective cell-based therapies for currently incurable diseases. Initial research is being directed to developing and characterising cell lines of potential therapeutic value in the treatment of spinal injury, Parkinson's disease, eye disease, epilepsy and Duchenne Muscular Dystrophy (DMD). Programmes to test SCS' proprietary stem cells in animal models of spinal cord injury have been initiated in a number of disease models and preclinical studies for the treatment of Duchenne Muscular Dystrophy are anticipated in 2007-8.

For further information on the company please visit:
www.stemcellsciences.com

www.biotechcapital.com.au